For iRhythm, two new JAMA studies could translate to big sales

iRhythm Technologies reported a promising second quarter from a financial standpoint, citing  a revenue of $35.5 million, up 55 percent from this time last year. But CEO Kevin King ' s major focus on the call was not earnings, but a pair of scientific studies published last month in the Journal of the American Medical Association and JAMA Cardiology. These studies and what they represent could crack the market wide open for iRhythm, King suggested.
Source: mobihealthnews - Category: Information Technology Source Type: news